Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial
Authors' conclusion
This post hoc analysis adds to the body of literature showing that glucagon-like peptide 1 receptor agonists added to standard type 2 diabetes therapy safely reduce the incidence of cardiovascular events in older adults with established cardiovascular disease. In this analysis, the risk-benefit profile was similar between younger and older age groups treated with albiglutide.
Study context
- Population
- Adults with T2D and CVD in the Harmony Outcomes trial
- Participants
- 9,462 adults
- Comparison
- Albiglutide vs placebo by age subgroup
- ≥65 yearsn = 4,748
- ≥75 yearsn = 1,140
- Primary endpoint
- Time to first MACE
Methodological detailsage subgroup analysis, Cox proportional hazards regression
- Age subgroup analysis
- Cox proportional hazards regression
Primary result
As reported in the abstract
MACE (albiglutide effect) by age subgroup
Hazard ratio (95% CI)P value
<65 years
0.66(0.53–0.82)
≥65 years
0.86(0.71–1.04)
age interaction p = .07<75 years
0.78(0.67–0.91)
≥75 years
0.70(0.48–1.01)
interaction p = .6Original publication
Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial. Diabetes Obes Metab. Published 6 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →